Vittorio Gentile

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1337579/publications.pdf

Version: 2024-02-01

51	1,560	393982	301761
papers	citations	19	39
		h-index	g-index

51	51	51	1017
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells.. Molecular and Cellular Biology, 1994, 14, 6584-6596.	1.1	259
2	Expression of tissue transglutaminase in Balb-C 3T3 fibroblasts: effects on cellular morphology and adhesion.. Journal of Cell Biology, 1992, 119, 463-474.	2.3	231
3	Tissue Transglutaminase-Catalyzed Formation of High-Molecular-Weight Aggregatesin Vitrols Favored with Long Polyglutamine Domains: A Possible Mechanism Contributing to CAG-Triplet Diseases. Archives of Biochemistry and Biophysics, 1998, 352, 314-321.	1.4	114
4	Isolation and Characterization of the Human Tissue Transglutaminase Gene Promoter. Journal of Biological Chemistry, 1995, 270, 9748-9756.	1.6	86
5	The importance of the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS Letters, 1995, 370, 27-31.	1.3	85
6	Lack of â€˜tissueâ€™ transglutaminase protein cross-linking leads to leakage of macromolecules from dying cells: relationship to development of autoimmunity in MRLlpr/lpr mice. Cell Death and Differentiation, 1997, 4, 463-472.	5.0	82
7	Transglutaminase-mediated modifications of the rat sperm surface in vitro. Science, 1984, 226, 852-855.	6.0	76
8	Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)n/Qn-expansion diseases?. Neurochemistry International, 2002, 40, 53-67.	1.9	68
9	Pathogenesis of Inclusion Bodies in (CAG)n/Qn-Expansion Diseases with Special Reference to the Role of Tissue Transglutaminase and to Selective Vulnerability. Journal of Neurochemistry, 2008, 72, 889-899.	2.1	66
10	The Human Tissue Transglutaminase Gene Maps on Chromosome 20q12 by in Situ Fluorescence Hybridization. Genomics, 1994, 20, 295-297.	1.3	51
11	Cereal dietary proteins with sites for cross-linking by transglutaminase. Phytochemistry, 1990, 29, 2801-2804.	1.4	36
12	Localization of the Human Prostate Transglutaminase (Type IV) Gene (TGM4) to Chromosome 3p21.33-p22 by Fluorescence in Situ Hybridization. Genomics, 1995, 27, 219-220.	1.3	33
13	Transglutaminases - Possible Drug Targets in Human Diseases. CNS and Neurological Disorders, 2004, 3, 99-104.	4.3	32
14	Transglutaminaseâ€catalyzed modifications of SVâ€IV, a major protein secreted from the rat seminal vesicle epithelium. International Journal of Peptide and Protein Research, 1990, 35, 117-122.	0.1	30
15	Changes in Tissue Transglutaminase Activity and Expression during Retinoic Acid-Induced Growth Arrest and Apoptosis in Primary Cultures of Human Epithelial Prostate Cells1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1463-1469.	1.8	29
16	Amines protect in vitro the celiac small intestine from the damaging activity of gliadin peptides. Gastroenterology, 1990, 99, 1668-1674.	0.6	27
17	tTGase/Gî±h protein expression inhibits adenylate cyclase activity in Balb-C 3T3 fibroblasts membranes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1357, 115-122.	1.9	27
18	Possible Role of the Transglutaminases in the Pathogenesis of Alzheimer's Disease and Other Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	23

#	Article	IF	Citations
19	Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases. Brain Research Bulletin, 2001, 56, 169-172.	1.4	20
20	Tissue transglutaminase expression affects hypusine metabolism in BALB/c 3T3 cells. FEBS Letters, 1998, 437, 34-38.	1.3	19
21	Abnormal Accumulation of tTGase Products in Muscle and Erythrocytes of Chorea-Acanthocytosis Patients. Journal of Neuropathology and Experimental Neurology, 2002, 61, 841-848.	0.9	16
22	Physio-pathological roles of transglutaminase-catalyzed reactions. World Journal of Biological Chemistry, 2010, 1, 181.	1.7	16
23	Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases. Current Medicinal Chemistry, 2009, 16, 4767-4773.	1.2	14
24	Cerebral Polyamine Metabolism: Inhibition of Spermidine Biosynthesis by Dicyclohexylamine. Journal of Neurochemistry, 1984, 42, 321-325.	2.1	12
25	Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2013, 8, 161-168.	0.9	11
26	Transglutaminase covalently incorporates amines into human immunodeficiency virus envelope glycoprotein GP120 in vitro. International Journal of Peptide and Protein Research, 1993, 42, 204-206.	0.1	10
27	B-lipotropin 61â€“76 and 61â€“91 fragments act as transglutaminase substrates in vitro. Neuropeptides, 1988, 11, 89-92.	0.9	9
28	Transglutaminase-Catalyzed Post-Translational Modifications of Proteins in the Nervous System and their Possible Involvement in Neurodegenerative Diseases. CNS and Neurological Disorders - Drug Targets, 2008, 7, 370-375.	0.8	8
29	Tissue transglutaminase and coeliac disease pathogenesis: potential molecular mechanisms for other human diseases. Neurochemistry International, 2002, 40, 79-83.	1.9	7
30	Transglutaminase-Catalyzed Reactions Responsible for the Pathogenesis ofCeliac Disease and Neurodegenerative Diseases: From Basic Biochemistry to Clinic. Current Medicinal Chemistry, 2006, 13, 1895-1902.	1.2	7
31	Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2014, 9, 76-84.	0.9	7
32	Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases. Amino Acids, 2013, 44, 111-118.	1.2	6
33	Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: celiac disease. Frontiers in Bioscience - Landmark, 2006, 11, 249.	3.0	5
34	Curcumin (Diferulolylmethane) Reduces Transglutaminase 2 Overexpression Induced by Retinoic Acid in Human Nervous Cell Lines. NeuroImmunoModulation, 2016, 23, 188-193.	0.9	5
35	Role of Transglutaminase-Catalyzed Reactions in the Post-Translational Modifications of Proteins Responsible for Immunological Disorders. Inflammation and Allergy: Drug Targets, 2008, 7, 24-29.	1.8	4
36	Neuronutraceuticals Modulate Lipopolysaccharide- or Amyloid-Î² 1-42 Peptide-Induced Transglutaminase 2 Overexpression as a Marker of Neuroinflammation in Mouse Microglial Cells. Applied Sciences (Switzerland), 2021, 11, 5718.	1.3	4

#	Article	IF	Citations
37	Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2014, 9, 101-109.	0.9	4
38	Possible roles of transglutaminases in molecular mechanisms responsible for human neurodegenerative diseases. AIMS Biophysics, 2016, 3, 529-545.	0.3	4
39	Biochemical mechanisms for a possible involvement of the transglutaminase activity in the pathogenesis of the polyglutamine diseases: Minireview article. Amino Acids, 2004, 26, 431-4.	1.2	3
40	Physiopathological Roles of Human Transglutaminase 2. Advances in Enzymology and Related Areas of Molecular Biology, 2011, 78, 47-95.	1.3	3
41	Cell-biomaterial interactions: role of transglutaminase enzyme. Journal of Materials Science: Materials in Medicine, 1996, 7, 707-711.	1.7	2
42	TISSUE TRANSGLUTAMINASE EXPRESSION IN QUAIL EPIPHYSEAL CHONDROCYTES. Cell Biology International, 1999, 23, 41-49.	1.4	2
43	Transglutaminases as Possible Therapeutic Targets in Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2010, 5, 195-202.	0.9	2
44	Transglutaminase Activity as a Possible Therapeutical Target in Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2014, 8, 235-242.	0.9	2
45	Pathophysiological Roles of Transglutaminase - Catalyzed Reactions in the Pathogenesis of Human Diseases. Inflammation and Allergy: Drug Targets, 2012, 11, 278-284.	1.8	1
46	Transglutaminase inhibition: possible therapeutic mechanisms to protect cells from death in neurological disorders. AIMS Molecular Science, 2017, 4, 399-414.	0.3	1
47	Transglutaminase inhibition: A therapy to protect cells from death in neurodegeneration?. World Journal of Biological Chemistry, 2012, 3, 184.	1.7	1
48	Spermine binding to subsynaptosomal fractions of rat brain cortex. Neurochemical Research, 1988, 13, 369-376.	1.6	0
49	Possible roles of transglutaminases in molecular mechanisms responsible for cancer and human neurodegenerative diseases. Translational Medicine Reports, 2017, 1, .	0.8	0
50	Possible pathophysiological roles of transglutaminase-catalyzed reactions in the pathogenesis of human neurodegenerative diseases. AIMS Biophysics, 2015, 2, 441-457.	0.3	0
51	Transglutaminase inhibition: possible therapeutic mechanisms to protect cells from death in neurological disorders `. , 2017, 1, 026-038.		0